No cell-based intradiscal therapy has FDA approval for degenerative disc disease in the United States. The EU has not licensed any disc regeneration cell product as a medicinal therapy. All intradiscal treatments remain investigational or delivered under regulated research protocols. Some European countries permit intradiscal cell injection under national compassionate frameworks for chronic, refractory cases. Regulatory distinction between 'treatment' and 'research' varies; transparency and informed consent are essential.
Chronic back pain frequently stems from degenerative disc disease—loss of hydration and structural integrity in intervertebral discs—compounded by facet joint arthritis and paraspinal muscle atrophy. Stem cell strategies target the nucleus pulposus (disc centre), where placental mesenchymal stem cells (MSCs) may regenerate proteoglycan matrix and restore biomechanical function. Exosomes derived from stem cells penetrate the avascular disc environment and deliver anti-inflammatory proteins that suppress catabolic pathways. Unlike surgical fusion, which immobilises segments, cell-based approaches aim to restore disc biology whilst preserving motion. MSCs also modulate neuropathic pain via immune suppression, addressing pain signalling independent of structural restoration. Thirty-five registered trials globally investigate disc regeneration and pain outcomes; two actively recruit new participants.
我是候选人吗？ → · Back & Disc Degeneration: full overview → · 脊柱和椎间盘退行性变成本 → · Cost →
由 StemCellAtlas 的编辑团队进行医学审查，与Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) 合作诊所 Stem Plus（索菲亚）的，根据 ISSCR、FDA 和 EMA 指南。 Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估